10:01 AM EDT, 07/22/2024 (MT Newswires) -- MyMD Pharmaceuticals ( MYMD ) said Monday it has rebranded to TNF Pharmaceuticals to reflect its focus on targeting TNF-alpha for immune and metabolic system regulation.

TNF's stock will begin trading under the new Nasdaq Capital Market symbol "TNFA" before the market opens on Wednesday.

The drugmaker said it plans to advance its clinical development of TNF-alpha inhibitor drug MYMD-1 in sarcopenia, an age-related loss of muscle mass and strength, into mid-stage trials.

Shares of the company were up 1.2% in recent Monday trading.

Price: 1.80, Change: +0.02, Percent Change: +1.18